Menlo report finds US health AI spend doubled to $3.7bn as copilots grow five-fold
Clinical copilots reached $550m and front-office tools $450m, while incumbent record vendors took 68% of new ambient scribing spending in 2026.
By World Nexus Group Editorial
Spending on AI in US healthcare has reached $3.7 billion, more than twice the figure a year earlier, according to a Menlo Partners report covered on 16 November 20261. The report, based on a poll of more than 550 US healthcare and life sciences executives, finds that the fastest growth has moved away from ambient scribing and towards clinical copilots and front-office tools1.
Where the money is going
Providers account for 77% of healthcare AI spending, so their choices set the direction of the market1. Spending on clinical copilots, which support clinicians in patient care, grew roughly five-fold to $550 million1. Patient engagement and front-office tools grew by about the same multiple to $450 million1. By contrast, ambient scribing and coding and billing grew by less than double year on year, although both remain popular administrative uses1.
The report also tracks who wins the contracts. In ambient scribing the incumbents are pulling ahead: established health IT vendors, including Microsoft's Dragon Copilot and Epic's Art, took 68% of new ambient scribing spending in 2026 and now hold 46% of that market1. Start-ups lost 13% of market share in the category1.
In the growth areas the pattern reverses. More than two-thirds of providers would rather keep coding, billing and chart review inside their electronic health record, but only 16% said the same of patient navigation1. For clinical copilots, OpenEvidence is the most popular choice among respondents1.
What it means for the market
For investors, the figures split the provider AI market in two. Administrative tasks that sit close to the record are consolidating around the record vendors, while copilots and patient-facing tools remain open to newer companies1. That split is already changing start-up strategy. The report notes that Abridge has agreed a deal with Availity on real-time prior authorisation, and that Heidi has partnered with R1 to bring payer prior authorisation policies into the clinical encounter, as scribing companies move into adjacent work1.
Public money and regulators are also widening the field for clinical decision tools. Utah's regulatory sandbox has allowed Doctronic to handle prescription renewals for 191 medications, and ARPA-H is putting $62.7 million into round-the-clock AI agents to monitor heart failure patients between visits, with FDA approval as the aim1.
For corporate development teams, the report ties the start-ups' loss of share in scribing directly to their push into other workflows1. Its authors describe healthcare AI expanding into clinical decision support, drug discovery and patient interaction, tasks that were traditionally left to people1.
Caveats
The data come from a survey of US executives, so the figures describe the US market only and rest on what respondents report1. The source does not set out the report's method for sizing spending, and an earlier version of the coverage misstated the total before it was corrected to $3.7 billion1.
Sources
This briefing summarises publicly available research and reporting for information only. It is not medical, investment or legal advice. Follow the sources listed for the primary research and reporting.